Physician profile
John E Call
NPI 1376997767
$67,534.06
in general payments reported to CMS, 2019-2025
31 companies · $23K in 2025
The $23K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $82.87 · 2021: $971 · 2022: $2,653 · 2023: $16K · 2024: $24K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Food and Beverage: $12K · Travel and Lodging: $2,857 · Consulting Fee: $2,268 · Education: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,875.00 |
| Food and Beverage | $12,068.81 |
| Travel and Lodging | $2,856.94 |
| Consulting Fee | $2,268.00 |
| Education | $484.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $29,689.58 | 2021-2025 | Dupixent |
| Genzyme Corporation | $24,567.08 | 2021-2025 | |
| Abbvie INC. | $2,772.80 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Lilly USA, LLC | $1,731.90 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $1,176.74 | 2021-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $1,083.32 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Arcutis Biotherapeutics, INC. | $869.84 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $802.75 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $735.98 | 2022-2025 | |
| Ucb, INC. | $657.07 | 2022-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $641.50 | 2021-2025 | Siliq, Jublia, Arazlo |
| E.R. Squibb & Sons, L.L.C. | $446.36 | 2022-2025 | Sotyktu |
| Amgen INC. | $326.65 | 2020-2024 | Otezla |
| Dermavant Sciences, INC. | $315.03 | 2023-2024 | Vtama |
| Journey Medical Corporation | $307.54 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $272.55 | 2023-2025 | |
| Galderma Laboratories, L.P. | $194.36 | 2021-2025 | Nemluvio, Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.62 | 2022-2025 | Spevigo |
| Leo Pharma INC. | $174.33 | 2022-2025 | Adbry, Anzupgo |
| Celgene Corporation | $131.00 | 2019 | |
| Almirall LLC | $81.94 | 2024-2025 | Klisyri |
| Fresenius Kabi USA, LLC | $63.86 | 2024 | Idacio |
| Vyne Pharmaceuticals INC. | $60.55 | 2020 | |
| Allergan, INC. | $55.57 | 2021 | |
| Botanix Sb INC | $47.48 | 2025 | Sofdra |
| Organon LLC | $34.82 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $33.77 | 2023 | Valchlor |
| Hill Dermaceuticals, INC. | $23.67 | 2025 | Tolak |
| Dermira, INC. | $16.97 | 2021 | |
| Strata Skin Sciences, INC. | $16.08 | 2024 | Xtrac |
| Cipher Pharmaceuticals US LLC | $15.35 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Call listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.